BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, has been ...
Therapies from Johnson & Johnson and Takeda Pharmaceutical have validated a particular rare genetic mutation as a viable drug target for treating lung cancer. Scorpion Therapeutics aims to best those ...
Scorpion Therapeutics Inc. has named STX-241 as its next development candidate. STX-241 is an orally bioavailable, highly selective, central nervous system (CNS)-penetrant, fourth-generation EGFR ...
After watching its stock price drop earlier this week by more than 20% following the publication of a stinging report from the activist short-seller firm Scorpion Capital, the DNA weaver Twist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback